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We have demonstrated the feasibility of detecting and quantifying six cell-cycle-related nuclear markers (Ki67, pRb, p27, phospho-
p27 (phosphorylated p27), phospho-pRb (phosphorylated pRb), phospho-HH3 (phosphorylated histone H3)) in plucked human
scalp and eyebrow hair. Estimates of the proportion of plucked hairs that are lost or damaged during processing plus the intra- and
intersubject variability of each nuclear marker with these techniques are provided to inform sizing decisions for intervention studies
with drugs potentially impacting on these markers in the future.
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Plucked human hairs contain proliferating cells within the hair
sheath (Moll, 1996; Gho et al, 2004); they are therefore potentially
attractive as an easily accessible tissue in which to assess the
pharmacodynamic (PD) effects of drugs that interfere with cell
proliferation. Skin biopsies have already been used to similar ends
during the development of a number of agents targeted against the
epidermal growth factor receptor (Albanell et al, 2002; Malik et al,
2003; Salazar et al, 2004; Vanhoefer et al, 2004). Plucked hairs
would offer certain advantages over skin biopsies for these
purposes including improved tolerability, a greater potential for
multiple time-point analyses and the possibility of a higher signal
within hair follicles for certain key biomarkers compared to the
cells of the epidermis (Albanell et al, 2002). We have developed a
technique for quantifying cell-cycle-related proteins within the
sheath cells of plucked human hair.
MATERIALS AND METHODS
Trial design
In all, 12 healthy Caucasian males, within the age range 18–45
years, and with scalp hair greater than or equal to 5mm in length,
were recruited. Following thorough combing to remove any loose
hairs, five suitable hairs with visible bulbs were plucked from each
of the left eyebrow, right eyebrow and four different scalp sites
using a pair of blunt-nosed forceps. Each set of five hairs was
trimmed with scissors to a workable length (approximately 1cm),
retaining the bulb end of each hair, and then immersed in
prelabelled 1.5ml microcentrifuge tubes containing 1ml 100%
acetone at 41C. Plucked hairs without visible bulbs were discarded
and not processed.
Immunohistochemistry (IHC) and signal quantification
Hair processing Following acetone fixation for 10min, each hair
was air-dried for 10min and then placed, in batches of five from
each sampling site, in 1ml of 0.5 M, pH 7.6, Tris-buffered saline.
Hair IHC In our hands, it was not possible to paraffin embed and
then section the hairs for later staining without producing
significant loss or damage of the fragile material; we therefore
developed techniques based on staining intact hairs followed by
rigid epoxy resin embedding and then sectioning.
Briefly, a peroxidase block (5min at room temperature),
followed by a nonspecific protein block (30min at room
temperature), was employed on the intact hairs. A primary
antibody, or buffer for negative controls, was then applied (anti-
Ki67 at 1:100 for 1h at room temperature, DAKO M7240; anti-pRb
at 1:200 for 48h at 41C, DAKO 7131; anti-phospho-pRb
(phosphorylated pRb) at 1:200 for 48h at 41C, BIOSOURCE 44-
584; anti-p27 at 1:100 for 48h at 41C, Research Diagnostics RDI-
P27CABR; anti-phospho-P27 (phosphorylated p27) at 1:100 for
48h at 41C, UPSTATE 06-996 and phospho-HH3 (phosphorylated
histone H3) at 1:200 for 48h at 41C, Upstate 06-570). The
specificity of all antibodies was validated independently by the
detection of single bands on Western blots of MCF7 cell extracts,
by signal abolition on blocking peptide preincubation (where
available) and by signal abolition on alkaline phosphatase
preincubation for phospho-specific epitopes. The secondary
system used was the EnVisiont Plus HRP (horse radish
peroxidase) system (mouse and rabbit). The EnVisiont polymer
was incubated with the hairs for 30min at room temperature. The
chromogen DAB (30-diaminobenzidine) was applied for 5min at
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sroom temperature. The hairs were then individually mounted in an
aqueous mount, and a coverslip applied. All washes were with
0.5 M, pH 7.6, Tris-buffered saline with 0.5% Tween-20.
Hair staging The hairs were examined by light microscopy to
evaluate nuclear staining in terms of its presence/absence, site of
staining and stage of hair. Each hair with a visible bulb and root
sheath was photographed and staged (0, 1, 2 or 3), according to a
bespoke system based on the distance of the lower margin of the
sheath from the base of the bulb (Figure 1). Stage 0¼sheath
encompassing the bulb, stage 1p150mm, stage 2¼150–699mm
and stage 3X700mm. Hairs noted to be without visible bulbs and
sheaths that had not been excluded previously at the initial by-eye
examination were discarded at this point. Every hair with both a
bulb and sheath present was taken forward for embedding into
epoxy resin.
Hair embedding The hairs on the slides were placed in individual
dishes of distilled water overnight to float off the coverslips. The
hairs were loaded onto an automated EMTP processor (Leica) for
dehydration and impregnation with freshly prepared resin (Taab
Araldite Cy212 Resin)a t4 0 1C for a minimum of 1h. The resin was
then polymerised at 651C overnight.
Hair sectioning The whole of each hair was sectioned tangentially
at 2mm (approximately 120 sections per hair). Serial sections were
collected and placed on glass slides. The coverslips were then
applied to the slides with distrene–plasticiser–xylene (DPX).
Hair quantification The slides were examined by light micro-
scopy, and three tangential sections from each hair sheath, at the
level nearest to the bulb, with clear positive labelled nuclei and
minimal background staining were identified and quantified
(Figure 2). The total area of the sheath section evaluated and the
number of positive labelled nuclei on each of these three sections
were assessed using a KS400, version 3.0, image-analysis system
within the area of the screen at  20 magnification. Data from each
section were recorded as the number of positive nucleimm
 2.
Figure 1 Exploratory staging system used within study on plucked scalp hairs (Ki67-stained hairs). Stage 0 (A)¼sheath encompassing bulb. Stage 1
(B)¼sheath o150mm from the base of the bulb. Stage 2 (C)¼sheath 150–699mm from the base of the bulb. Stage 3 (D)¼sheath 4700mm from the
base of the bulb. The scale bars represent 500mm.
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sStatistical analysis
A number of different analysis of variance (ANOVA) models were
explored for these data in order to investigate site and stage effects
separately. Data were collected on three adjacent sections from
each hair, and averaged before analysis.
In all analyses, log-transformed data were used. Zero counts
(and missing values due to high background) were substituted
with the minimum observed level for each marker in lieu of a limit
of quantification (LoQ). A statistical significance level of Po0.05
was used.
RESULTS
Even when the length of hair protruding from the scalp was only
5mm, the length of plucked hair, including the bulb and sheath,
was often double this, making handling of the hairs relatively easy.
All six markers produced discrete nuclear staining on the resin-
embedded sections within both the scalp and eyebrow hairs (cf.
Figure 2 for representative Ki67 sections), with no staining present
on the negative controls.
Each marker was measured in a total of 40 scalp hairs from eight
different subjects and 20 eyebrow hairs from four different
subjects. The proportions of hairs providing signals quantified as
greater than zero, and the drop-off rates of hairs at each point in
the preparation procedure are presented in Table 1.
An ANOVA model with random effect term for subject, and
fixed effect term for site, was fitted to the mean quantitative score
per hair data to explore the effect of body site (scalp vs eyebrow)
for each marker. The results of this analysis are shown in Table 2.
The numbers of scalp hairs stained and staged within each
classification 0–3, based on the distance from the lower end of the
sheath to the base of the bulb, are shown in Table 3. All eyebrow
hairs visualised had the sheath around the bulb, and therefore were
not individually staged using this system.
An exploratory indication of comparative variation between
hairs from the same subjects at the same time, and from between
different subjects, was possible using the mean marker levels per
hair. The effect on intra- and intersubject coefficients of variation
(CV) of differences between stages was investigated by comparing
components of variation when the ANOVA model included or
excluded stage as a fixed factor (Table 4).
DISCUSSION
Ki67-positive cells have previously been demonstrated within the
outer root sheath of plucked human hairs by immunofluorescence
(Gho et al, 2004), and epithelial outgrowth has been demonstrated
in explant cultures of such plucked hairs in vitro (Moll, 1996). We
looked at six different cell-cycle-related nuclear markers by IHC in
plucked human scalp and eyebrow hair from healthy male
Figure 2 Representative staining of whole eyebrow hair with antibodies directed against Ki67, showing punctate nuclear staining (A). Tangential section of
same eyebrow hair after embedding in resin used for Ki67 quantification (B). Representative staining of whole scalp hair (stage 1) with antibodies directed
against Ki67, showing punctate nuclear staining (C). Tangential section of same scalp hair after embedding in resin, showing delineated area nearest to bulb
on the selected section used for Ki67 quantification (D). The scale bars represent 200mm.
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svolunteers. The proportions of suitable hairs from scalp and
eyebrow that were lost or damaged during processing were 18 and
10%, respectively (Table 1). For fully processed scalp and eyebrow
hairs across all markers, a total of 20 and 44%, respectively, were
also unquantifiable either due to a zero positive nuclear count or
due to high background staining (Table 1). It is impossible from
this data set to distinguish between unquantifiable counts due to
processing failures and genuine biological zeros. However, the
relative positive nuclear count frequencies for the different
markers in other healthy human tissues are fully consistent with
the majority of these zero counts being ‘biological’. Whether low
levels of markers could be reliably increased prestudy in order to
make them more practicable, for example, through the use hair
stimulants such as minoxidil (Messenger and Rundegren, 2004), is
currently unknown. The final evaluation of the usefulness of any of
these markers as study end points will depend on demonstrating
PD activity on them within a future drug-intervention study. We
would suggest that in any future drug-intervention study involving
PD end points in plucked human hair, zero counts and high
background hairs are also fully recorded and analysed in case the
effect of the drug is primarily to increase the proportion of
biological zeros among the hairs. Zero counts due to processing
failures, should, in theory, remain constant over time.
With regard to the body site with the highest marker levels from
which to pluck hairs, there is a clear statistically significant
difference that favours scalp over eyebrow for Ki67, total p27 and
phospho-p27, with all other markers also having higher expression
in scalp hairs than in eyebrows (Table 2).
The normal human hair cycle can be divided into three separate
phases: anagen, catagen and telogen (Sperling, 1991). During pilot
work for the current study, it was apparent that plucked scalp hairs
fell within four broadly distinct morphological groups, which we
referred to as stages 0–3, based on the distance of the sheath from
the base of the bulb under light microscopy (Figure 1). While the
stage 0 hairs fitted the description of clubbed telogen hairs very
well, stages 1–3 were thought to represent the impact of
anatomical weak points within the anagen follicle favouring
breakage of the inner and/or outer sheath at particular distances
Table 1 Proportion of quantifiable hairs (‘success rate’) by marker from scalp and eyebrow
Plucked Stained Through to resin Lost/damaged Zero count High background Quantified 40 (% of total)
Scalp
Ki67 40 35 35 6 0 0 34 (85%)
Total pRb 40 36 32 5 4 0 31 (78%)
Phospho-pRb 40 37 24 5 14 1 20 (50%)
Total p27 40 35 30 10 1 0 29 (73%)
Phospho-p27 40 36 21 10 12 1 17 (43%)
Phospho-HH3 40 33 27 8 6 10 16 (40%)
Total 240 212 169 44 (18%) 37 (15%) 12 (5%) 147 (61%)
Eyebrow
Ki67 20 20 18 2 2 0 16 (80%)
Total pRb 20 19 19 1 0 0 19 (95%)
Phospho-pRb 20 20 13 0 7 2 11 (55%)
Total p27 20 20 8 1 11 1 7 (35%)
Phospho-p27 20 20 4 0 20 0 0 (0%)
Phospho-HH3 20 14 10 8 6 4 2 (10%)
Total 120 113 72 12 (10%) 46 (38%) 7 (6%) 55 (46%)
Phospho-p27¼phosphorylated p27; phospho-pRb¼phosphorylated pRb; phospho-HH3¼phosphorylated histone H3. The numbers of hairs in the four columns on the right-
hand side add up to the total number of hairs plucked. Hairs could be registered as lost/damaged, or quantified as having no staining, either before or after being taken through to
resin.
Table 2 Mean per hair data analysis by site (scalp/eyebrow)
Scalp glsmean
(nucleimm
 2)
Scalp N (number
of hairs)
Eyebrow glsmean
(nucleimm
 2)
Eyebrow N (number of
hairs)
P-value for site
difference
Ki67 4535.1 34 2405.0 18 0.009
Total pRb 6144.1 35 5749.9 19 0.837
Phospho-pRb 2124.3 35 1383.7 20 0.554
Total p27 7903.9 30 2427.8 20 o0.001
Phospho-p27 1783.8 30 929.8 20 0.023
Phospho-HH3 871.0 32 397.3 12 0.198
Phospho-p27¼phosphorylated p27; phospho-pRb¼phosphorylated pRb; phospho-HH3¼phosphorylated histone H3. The data included zero counts and high background
counts expressed as LoQ values.
Table 3 Number of hairs within each stage classification for scalp hairs
based on distance of the sheath from the base of the hair bulb (n¼200
hairs stained and staged)
Stage 0 Stage 1 Stage 2 Stage 3
All subjects (n¼200) 13 (7%) 50 (25%) 79 (40%) 58 (29%)
Per subject ranges (0–18%) (5–56%) (5–80%) (0–85%)
In parentheses, each stage is also shown as a percentage of the total number of hairs
acquired from all subjects, and as the range of percentages seen within individual
subjects.
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sfrom the base of the bulb. Since there is some evidence that
different sections along the sheath of plucked human hair may
have different proliferative potentials (Moll, 1996), we developed a
system to classify prospectively all hairs within the current study
into stages 0–3 (Table 3), looking for any influence of these
different stages on the quantitative IHC results.
Given the caveat that there were often small numbers of hairs
present within each stage, while there was a difference in some
marker levels between hairs at different stages, the pattern was not
entirely consistent across all markers, and, in the majority of cases,
failed to reach statistical significance (data not shown).
Initial estimates of the intra- and intersubject components of
variance for the different markers in scalp hair are shown in
Table 4. It is likely that the reliability of these CV estimates could
be improved further if a larger data set were used in terms of the
number of individuals or number of hairs per individual, or if
multiple sections from each hair were counted for each marker,
particularly if the sections were stepped to avoid the same cell
being counted more than once. It can be seen by comparing
corresponding cells in Table 4 that, even when the hair stage effect
is highly significant (e.g. total pRb – Po0.001 for stage difference),
the improvement in intrasubject CV due to the stage adjustment is
modest, with a greater impact on intersubject CV, perhaps
reflecting a greater variation in the distribution of stages between
subjects. Therefore, it seems unlikely that allowing for the effect of
stage would make much difference in future studies primarily
using within-subject comparisons. The potential impact of factors
such as ethnicity and gender, or of any relevant pre-study
treatment, for example, whether hair follicles are synchronised in
anagen during the recovery from cytotoxic chemotherapy-induced
alopecia, is currently unknown.
In conclusion, we have demonstrated the feasibility of detecting
and quantifying a range of cell-cycle-related nuclear markers in
plucked human hair, which could be used as PD end points in
intervention studies using drugs that interact with these pathways.
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